IP Library Granted Patent US 8,653,244
Granted Patent B2
US 8,653,244 · App. 13/509,235 · Granted Feb 18, 2014

Anti-epidermal growth factor receptor antibodies and uses thereof

Inventors: David Weaver (Beijing, CN); Michael Rynkiewicz (Beijing, CN); Cheng Cao (Beijing, CN); Yanwen Jin (Beijing, CN)
Assignee: Guangzhou Yunyuan Biotech Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,653,244
App. No.
13/509,235
Granted
Feb 18, 2014
Kind
B2
Abstract

The present invention discloses humanized anti-epidermal growth factor receptor antibodies, which have favorable binding activity (the binding affinity being 6.13×10 −10 mol/L) and are able to inhibit the growth and migration of tumor cells. The present invention also discloses the preparation methods and uses of the antibodies.

Claims (17)

1. An antibody, wherein the heavy chain variable region of the antibody has the amino acid sequence as set forth by SEQ ID NO. 3, and the light chain of the antibody has the amino acid sequence as set forth by SEQ ID NO. 2.

2. The antibody according to claim 1 , wherein the antibody comprises a heavy chain and the light chain, and the heavy chain comprises the heavy chain variable region and a heavy chain constant region.

3. The antibody according to claim 2 , wherein the heavy chain constant region comprises an amino acid sequence as set forth by SEQ ID NO. 11.

4. An inhibitor for inhibiting (1) a signal transduction pathway of epidermal growth factor receptor or (2) a colon cancer cell invasion, wherein an active ingredient of the inhibitor is the antibody of claim 1 .

5. The inhibitor according to claim 4 , wherein the colon cancer cell is a SW480 cell.

6. A drug for treating colon cancer, wherein an active ingredient of the drug is the antibody of claim 1 .

7. The drug according claim 6 , wherein the tumor cell is a SW480 cell.

8. A method for inhibiting signal transduction pathway of epidermal growth factor receptor comprising preparing an inhibitor of the antibody of claim 1 and administering the inhibitor in an effective amount.

9. A method for inhibiting a colon cancer cell invasion comprising preparing an inhibitor of the antibody of claim 1 and administering the inhibitor in an effective amount.

10. The method according to claim 9 , wherein the tumor cell is a SW480 cell.

11. A method for treating colon cancer comprising preparing a drug comprising the antibody of claim 1 and administering the drug in an effective amount.

12. The method according to claim 11 , wherein the colon cancer cell is a SW480 cell.

13. A method of inhibiting signal transduction pathway of epidermal growth factor receptor comprising administering the antibody of claim 1 in an effective amount to an individual in need thereof.

14. A method of inhibiting a colon cancer cell invasion comprising administering the antibody of claim 1 in an effective amount to an individual in need thereof.

15. The method according to claim 14 , wherein the tumor cell is a SW480 cell.

16. A method of treating a colon cancer comprising administering the antibody of claim 1 in an effective amount to an individual in need thereof.

17. The method according to claim 16 , wherein the colon cancer is a SW480 cell.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 23, 2013
From: GUANGZHOU RECOMGEN BIOTECH CO., LTD.
To: GUANGZHOU YUNYUAN BIOTECH CO., LTD.
Reel/Frame 030475/0142 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 28, 2012
From: INSTITUTE OF BIOTECHNOLOGY CHINESE PLA ACADEMY OF MILITARY MEDICAL SCIENCES
To: GUANGZHOU RECOMGEN BIOTECH CO., LTD.
Reel/Frame 028862/0268 →
MERGER Recorded Aug 24, 2012
From: WEAVER, DAVID; RYNKIEWICZ, MICHAEL; CAO, CHENG; JIN, YANWEN
To: INSTITUTE OF BIOTECHNOLOGY CHINESE PLA ACADEMY OF MILITARY MEDICAL SCIENCES
Reel/Frame 028843/0807 →
Priority Claims (1)
CN 2009 1 0237804 · Nov 11, 2009 · national
Continuity (1)
Related Publication 20120321643A1 · Dec 20, 2012